The objective of this study is to determine if the action of the drug called clopidogrel, that you will start taking, will be decreased by another drug called atorvastatin, that you will also start taking. Clopidogrel is an oral antiplatelet agent that has been shown to prevent strokes and heart attacks. Atorvastatin is a cholesterol lowering agent.

Twenty adults 18-75 years of age requiring cholesterol-lowering agent and antiplatelet agent therapy will be recruited for this study during their cardiology clinic visitation. In one group, antiplatelet agent (clopidogrel) regimen will be administered first, then followed by cholesterol-lowering medication (atorvastatin). In the second group, atorvastatin will be administered first, followed by clopidogrel.

A new test called the erythromycin breath test will be administered to you three times during the study to measure how your liver will metabolize these drugs. Blood samples will also be obtained to assess platelet function. The criteria for exclusion are patient refusal or inability to give written consent, patients with allergic reaction to erythromycin, patients with known bleeding problems, liver disease, significant lung disease kidney disease and pregnancy. Patients with psychiatric impairment and documented history of substance abuse will also be excluded from the study.

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Parallel Assignment

Intervention(s) in this Clinical Trial

• Drug: Clopidogrel
• Drug: Atorvastatin

Inclusion Criteria:

• Males and females age 18-75 years of age without bias in racial and ethnic background, undergoing percutaneous coronary intervention requiring antiplatelet therapy: 1.
• Patients presented to cardiology clinic requiring cholesterol lowering agent 2.
• Patients presented to cardiology clinic requiring antiplatelet agent.

Exclusion Criteria:

• Refusal or inability to give written consent
• Allergic reaction to erythromycin
• Have known bleeding problems, liver disease, significant lung disease kidney disease
• Pregnancy
• Psychiatric impairment and documented history of substance abuse

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 75 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: National Center for Research Resources (NCRR)

Overall Clinical Trial Officials and Contacts

Overall Contact: Wei C. Lau, M.D. 1-734-936-4280 

Information obtained from ClinicalTrials.gov on August 21, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00004564

Study ID Number: NCRR-M01RR00042-1659

ClinicalTrials.gov Identifier: NCT00004564

Health Authority: United States: Federal Government